Hepatocellular carcinoma (HCC) remains a highly prevalent malignancy worldwide with limited therapeutic options and frequent resistance to treatment, necessitating the development of targeted pharmacological interventions. Although artesunate, a derivative of the widely used antimalarial drug artemisinin, has emerged as a promising anticancer candidate, the molecular basis underlying its antitumor activity in HCC has remained unclear.